Is there a role for statins in fungal infections?

被引:13
作者
Bergman, Peter W. [1 ]
Bjorkhem-Bergman, Linda
机构
[1] Karolinska Univ Hosp, Div Clin Microbiol, Dept Lab Med, S-14186 Huddinge, Sweden
关键词
antifungal agents; clinical studies; drug interaction; fungal infections; statins; COA REDUCTASE INHIBITORS; DRUG-DRUG INTERACTIONS; IN-VITRO; CANDIDA-ALBICANS; ANTIFUNGAL ACTIVITY; HEPATOCELLULAR-CARCINOMA; CRYPTOCOCCUS-NEOFORMANS; ASPERGILLUS-FUMIGATUS; MEVALONATE PATHWAY; DIABETES-MELLITUS;
D O I
10.1586/14787210.2014.856755
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
It has been hypothesized that statins, HMG-CoA reductase inhibitors, may be used to treat fungal infections. Here we review data on antifungal properties of statins, effects on the host inflammatory response as well as available clinical evidence. We conclude that: statins exhibit antifungal properties in vitro although at supraphysiological concentrations; statins appear to have anti-inflammatory effects on host cells in vitro; statins have effects on fungal physiology beyond direct growth inhibition; clinical studies are scarce (n = 5), and their design is retrospective and observational, which is associated with a high risk of bias. Given the limited evidence for a beneficial effect of statins in fungal infection, randomized and controlled trials are highly warranted in this field.
引用
收藏
页码:1391 / 1400
页数:10
相关论文
共 63 条
[1]   Studies on the Antibacterial Effects of Statins - In Vitro and In Vivo [J].
Bergman, Peter ;
Linde, Charlotte ;
Putsep, Katrin ;
Pohanka, Anton ;
Normark, Staffan ;
Henriques-Normark, Birgitta ;
Andersson, Jan ;
Bjorkhem-Bergman, Linda .
PLOS ONE, 2011, 6 (08)
[2]   What is a relevant statin concentration in cell experiments claiming pleiotropic effects? [J].
Bjorkhem-Bergman, Linda ;
Lindh, Jonatan D. ;
Bergman, Peter .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (01) :164-165
[3]  
Björkhem-Bergman L, 2010, ANTICANCER RES, V30, P1105
[4]   Statin Treatment and Mortality in Bacterial Infections - A Systematic Review and Meta-Analysis [J].
Bjorkhem-Bergman, Linda ;
Bergman, Peter ;
Andersson, Jan ;
Lindh, Jonatan D. .
PLOS ONE, 2010, 5 (05)
[5]   Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase [J].
Bochar, DA ;
Stauffacher, CV ;
Rodwell, VW .
MOLECULAR GENETICS AND METABOLISM, 1999, 66 (02) :122-127
[6]   In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus [J].
Bordier, BB ;
Ohkanda, J ;
Liu, P ;
Lee, SY ;
Salazar, FH ;
Marion, PL ;
Ohashi, K ;
Meuse, L ;
Kay, MA ;
Casey, JL ;
Sebti, SM ;
Hamilton, AD ;
Glenn, JS .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :407-414
[7]   Hidden Killers: Human Fungal Infections [J].
Brown, Gordon D. ;
Denning, David W. ;
Gow, Neil A. R. ;
Levitz, Stuart M. ;
Netea, Mihai G. ;
White, Theodore C. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (165)
[8]   Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole [J].
Chamilos, G ;
Lewis, RE ;
Kontoyiannis, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :96-103
[9]  
Chen Y, 2013, EUR J CLIN PHARM
[10]   In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans [J].
Chin, NX ;
Weitzman, I ;
DellaLatta, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :850-852